BioSyent Future Growth

Future criteria checks 1/6

BioSyent is forecast to grow revenue at 12.9% per annum. EPS is expected to grow by 18.8% per annum.

Key information

n/a

Earnings growth rate

18.8%

EPS growth rate

Pharmaceuticals earnings growth61.4%
Revenue growth rate12.9%
Future return on equityn/a
Analyst coverage

Low

Last updated21 Nov 2024

Recent future growth updates

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Recent updates

BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

Nov 23
BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Aug 30
BioSyent's (CVE:RX) Dividend Will Be CA$0.045

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Mar 22
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Feb 09
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14
BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18
BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07
BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17
BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Earnings and Revenue Growth Forecasts

TSXV:RX - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202646N/AN/AN/A1
12/31/202542N/AN/AN/A1
12/31/202435N/AN/AN/A1
9/30/202435727N/A
6/30/202434723N/A
3/31/202433777N/A
12/31/202332655N/A
9/30/202331667N/A
6/30/202329555N/A
3/31/202327534N/A
12/31/202228545N/A
9/30/202228645N/A
6/30/202228666N/A
3/31/202228655N/A
12/31/202129655N/A
9/30/202127555N/A
6/30/202126444N/A
3/31/202124456N/A
12/31/202022477N/A
9/30/2020224108N/A
6/30/202023567N/A
3/31/202023545N/A
12/31/201921444N/A
9/30/201922514N/A
6/30/201921545N/A
3/31/201922656N/A
12/31/201822666N/A
9/30/201822567N/A
6/30/2018226N/A7N/A
3/31/2018215N/A7N/A
12/31/2017215N/A7N/A
9/30/2017205N/A6N/A
6/30/2017195N/A5N/A
3/31/2017184N/A5N/A
12/31/2016184N/A4N/A
9/30/2016174N/A3N/A
6/30/2016174N/A4N/A
3/31/2016164N/A4N/A
12/31/2015154N/A3N/A
9/30/2015154N/A3N/A
6/30/2015144N/A3N/A
3/31/2015134N/A3N/A
12/31/2014123N/A4N/A
9/30/2014113N/A3N/A
6/30/2014103N/A2N/A
3/31/201492N/A2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if RX's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if RX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RX's revenue (12.9% per year) is forecast to grow faster than the Canadian market (4.7% per year).

High Growth Revenue: RX's revenue (12.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 10:58
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioSyent Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Scott CurtisCantor Fitzgerald Canada Corporation
Tania Armstrong-WhitworthCormark Securities Inc.